Oncotarget

Research Papers:

Acceleration of leukocytes’ epigenetic age as an early tumor and sex-specific marker of breast and colorectal cancer

Danielle Fernandes Durso, Maria Giulia Bacalini, Claudia Sala, Chiara Pirazzini, Elena Marasco, Massimiliano Bonafé, Ítalo Faria do Valle, Davide Gentilini, Gastone Castellani, Ana Maria Caetano Faria, Claudio Franceschi, Paolo Garagnani and Christine Nardini _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:23237-23245. https://doi.org/10.18632/oncotarget.15573

Metrics: PDF 1438 views  |   HTML 1627 views  |   ?  


Abstract

Danielle Fernandes Durso1,2,*, Maria Giulia Bacalini3,*, Claudia Sala4,9, Chiara Pirazzini3, Elena Marasco1, Massimiliano Bonafé1, Ítalo Faria do Valle4, Davide Gentilini5, Gastone Castellani4,9, Ana Maria Caetano Faria6, Claudio Franceschi3,*, Paolo Garagnani1,7,8,9,*, Christine Nardini10,11,*

1Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum-University of Bologna, Bologna, Italy

2National Counsel of Technological and Scientific Development (CNPq), Ministry of Science Technology and Innovation (MCTI), Brasilia, Brazil

3IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

4Department of Physics and Astronomy, University of Bologna, Bologna, Italy

5Istituto Auxologico Italiano IRCCS, Cusano Milanino, Milan, Italy

6Biochemistry and Immunology Department, Biological Sciences Institute, Federal University of Minas Gerais, Belo Horizonte, Brazil

7Applied Biomedical Research Center, S. Orsola-Malpighi Polyclinic, Bologna, Italy

8Interdepartmental Center “L. Galvani”, University of Bologna, Bologna, Italy

9Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet at Huddinge University Hospital, Stockholm, Sweden

10Personal Genomics S.r.l., Verona, Italy

11CNR IAC “Mauro Picone”, Rome, Italy

*These authors contributed equally to this work

Correspondence to:

Christine Nardini, email: christine.nardini.rsrc@gmail.com

Paolo Garagnani, email: paolo.garagnani2@unibo.it

Claudio Franceschi, email: claudio.franceschi@unibo.it

Keywords: epigenetic clock, ELOVL2, FHL2, cancer, blood

Received: October 19, 2016     Accepted: February 12, 2017     Published: February 21, 2017

ABSTRACT

Changes in blood epigenetic age have been associated with several pathological conditions and have recently been described to anticipate cancer development. In this work, we analyze a publicly available leukocytes methylation dataset to evaluate the relation between DNA methylation age and the prospective development of specific types of cancer. We calculated DNA methylation age acceleration using five state-of-the-art estimators (three multi-site: Horvath, Hannum, Weidner; and two CpG specific: ELOV2 and FHL2) in a cohort including 845 subjects from the EPIC-Italy project and we compared 424 samples that remained cancer-free over the approximately ten years of follow-up with 235 and 166 subjects who developed breast and colorectal cancer, respectively. We show that the epigenetic age estimated from blood DNA methylation data is statistically significantly associated to future breast and male colorectal cancer development. These results are corroborated by survival analysis that shows significant association between age acceleration and cancer incidence suggesting that the chance of developing age-related diseases may be predicted by circulating epigenetic markers, with a dependence upon tumor type, sex and age estimator. These are encouraging results towards the non-invasive and perspective usage of epigenetic biomarkers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15573